BiotechSectorInvesting.com

Corcept Therapeutics CORT Stock Price Hits Multi-Year High

Shares of pharmaceutical biotechnology company Corcept Therapeutics Inc. (NASDAQ stock symbol CORT) closed at $4.10 a share on Tuesday, the highest level since September 2007.

Corcept Therapeutics Incorporated is engaged in the discovery and development of drugs for the treatment of psychiatric disorders as well as metabolic issues.  CORT is engaged in the development of drugs for disorders that are associated irregular levels of cortisol, a steroid hormone.

Corcept Therapeutics' lead product is CORLUX.  CORLUX is glucocorticoid receptor II (GR-II) antagonist.  CORLUX is in Phase III clinical trials for the treatment of Cushing's Syndrome and psychotic depression.

Corcept Therapeutics CORT stock price quote

ALKS Stock Price Alkermes, Inc. $14.62

Shares of Alkermes, Inc. closed the week at $14.62 a share. ALKS stock price gained 2.38% during trading on Friday. Alkermes is an integrated biotechnology company.

Alkermes and Cephalon jointly market Vivitrol (formerly Vivitrex) a Naltrexone injection used for the treatment of alcoholism.

Alkermes manufactures a formulation of risperidone for the treatment of schizophrenia and bipolar disorder under the name Risperdal Consta.  Risperdal Consta is used by injection every two weeks.

In the pipeline, Alkermes is developing Exenatide as a once weekly treatment for type 2 diabetes.

ALKS stock price quote Alkermes

Sangamo Biosciences Inc. SGMO Stock Price +10.66%

Sangamo Biosciences Inc. rallied to the tune of 10.66% on Monday.  SGMO stock price closed at $3.53 a share after gaining 34 cents on the trading day.  SGMO engages the research and development of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification.

Sangamo Biosciences is based in Richmond, California. 

Sangamo Biosciences SGMO stock price

CHTP Stock Price Chelsea Therapeutics +22.82%

Shares of Chelsea Therapeutics International Ltd. (CHTP stock quote symbol) closed the week at $5.06 per share after gaining 22.82% on Friday.

CHTP stock has moved dramatically in the past month amid news of a mid-stage trial for a potential chronic-fatigue treatment and FDA approval to start a Phase II trial for its rheumatoid arthritis treatment. 

NORTHERA(TM) (droxidopa) is currently Chelsea Therapeutics most advanced drug candidate. NORTHERA(TM) (droxidopa) is an orally active synthetic precursor of norepinephrine which is initially being developed for the treatment of neurogenic orthostatic hypotension.

CHTP stock price quote Chelsea Therapeutics